Zacks: Analysts Anticipate Synthetic Biologics, Inc (SYN) to Post -$0.64 Earnings Per Share

Analysts expect Synthetic Biologics, Inc (NASDAQ:SYN) to report earnings per share of ($0.64) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Synthetic Biologics’ earnings. Synthetic Biologics reported earnings of ($0.70) per share in the same quarter last year, which would indicate a positive year over year growth rate of 8.6%. The business is expected to announce its next earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that Synthetic Biologics will report full year earnings of ($2.48) per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of ($2.54) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Synthetic Biologics.

Separately, William Blair reaffirmed an “outperform” rating on shares of Synthetic Biologics in a report on Thursday, February 28th.

NASDAQ:SYN traded down $0.01 during trading hours on Monday, hitting $0.63. 118,600 shares of the stock were exchanged, compared to its average volume of 326,436. Synthetic Biologics has a twelve month low of $0.51 and a twelve month high of $12.95.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Read More: What is included in the gross domestic product?

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.